These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 30729869)

  • 21. Standards and Methodological Rigor in Pulmonary Arterial Hypertension Preclinical and Translational Research.
    Provencher S; Archer SL; Ramirez FD; Hibbert B; Paulin R; Boucherat O; Lacasse Y; Bonnet S
    Circ Res; 2018 Mar; 122(7):1021-1032. PubMed ID: 29599278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective.
    Gomberg-Maitland M; Dufton C; Oudiz RJ; Benza RL
    J Am Coll Cardiol; 2011 Mar; 57(9):1053-61. PubMed ID: 21349396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New Therapeutic Paradigms and Guidelines in the Management of Pulmonary Arterial Hypertension.
    Hill NS; Cawley MJ; Heggen-Peay CL
    J Manag Care Spec Pharm; 2016 Mar; 22(3 Suppl A):S3-21. PubMed ID: 27003666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies.
    Waxman AB; Zamanian RT
    Am J Cardiol; 2013 Mar; 111(5 Suppl):1A-16A; quiz 17A-19A. PubMed ID: 23414683
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging therapies and future directions in pulmonary arterial hypertension.
    Gurtu V; Michelakis ED
    Can J Cardiol; 2015 Apr; 31(4):489-501. PubMed ID: 25840098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estradiol Metabolism: Crossroads in Pulmonary Arterial Hypertension.
    Tofovic SP; Jackson EK
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31877978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging treatments for pulmonary arterial hypertension.
    Rosenzweig EB
    Expert Opin Emerg Drugs; 2006 Nov; 11(4):609-19. PubMed ID: 17064221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK.
    Hansmann G; Apitz C
    Heart; 2016 May; 102 Suppl 2():ii67-85. PubMed ID: 27053700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Why there is a need to discuss pulmonary hypertension other than pulmonary arterial hypertension?
    Papathanasiou A; Nakos G
    World J Crit Care Med; 2015 Nov; 4(4):274-7. PubMed ID: 26557477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical trial designs in PAH: shifting from functional measurements to long-term clinical outcomes.
    Studer SM; Gilkin RJ
    Am J Manag Care; 2014 Mar; 20(6 Suppl):S115-22. PubMed ID: 24716456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular pathogenesis and current pathology of pulmonary hypertension.
    de Jesus Perez VA
    Heart Fail Rev; 2016 May; 21(3):239-57. PubMed ID: 26694808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imatinib mesylate for the treatment of pulmonary arterial hypertension.
    ten Freyhaus H; Dumitrescu D; Berghausen E; Vantler M; Caglayan E; Rosenkranz S
    Expert Opin Investig Drugs; 2012 Jan; 21(1):119-34. PubMed ID: 22074410
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of regenerative cell therapy for pulmonary arterial hypertension in animal models: a preclinical systematic review protocol.
    Suen CM; Zhai A; Lalu MM; Welsh C; Levac BM; Fergusson D; McIntyre L; Stewart DJ
    Syst Rev; 2016 May; 5():89. PubMed ID: 27225668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel strategies for treatment of pulmonary arterial hypertension.
    Jasińska-Stroschein M; Orszulak-Michalak D
    Postepy Hig Med Dosw (Online); 2017 Jul; 71(0):577-588. PubMed ID: 28791952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of pulmonary arterial hypertension-approved therapy in the treatment of non-group 1 pulmonary hypertension at US referral centers.
    Trammell AW; Pugh ME; Newman JH; Hemnes AR; Robbins IM
    Pulm Circ; 2015 Jun; 5(2):356-63. PubMed ID: 26064462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic Challenges And Advances In The Management Of Systemic Sclerosis-Related Pulmonary Arterial Hypertension (SSc-PAH).
    Argula RG; Ward C; Feghali-Bostwick C
    Ther Clin Risk Manag; 2019; 15():1427-1442. PubMed ID: 31853179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug repositioning in cancer: The current situation in Japan.
    Masuda T; Tsuruda Y; Matsumoto Y; Uchida H; Nakayama KI; Mimori K
    Cancer Sci; 2020 Apr; 111(4):1039-1046. PubMed ID: 31957175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Update: Preclinical developments for the treatment of pulmonary arterial hypertension].
    Janssen W; Ghofrani HA; Weissmann N; Grimminger F; Schermuly RT
    Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S157-9. PubMed ID: 19718604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenges and opportunities of drug repositioning.
    Novac N
    Trends Pharmacol Sci; 2013 May; 34(5):267-72. PubMed ID: 23582281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.